logo
  Join        Login             Stock Quote

Vivus (VVUS) Downgraded To 'Sell' By Brean Capital On Unwarranted Recent Optimism

 January 17, 2013 12:03 PM
 


(By Balaseshan) Vivus Inc. (NASDAQ: VVUS) shares were downgraded to "Sell" from "Hold" by Brean Capital due to unwarranted recent optimism.

Analyst Jonathan Aschoff said that as of his meeting with the biopharmaceutical company's management last week, still only 1 in 5 patients are covered by insurance for Qsymia, leading to continued prescription sticker shock even with free low dose drug as offered by Vivus ($150 versus almost twice that amount) for most patients.

Regarding the company's Get Started! program for free low dose Qsymia, management indicated that it is likely to alter it sometime after January, but it cannot get cheaper than free, and all that has been learned since launch indicates that paying more certainly will not reduce prescription abandonment, the analyst noted.

[Related -Futures Up After China Data; Citi (C), AT&T Inc. (T),Leap Wireless International Inc. (LEAP) In Focus]

In relation to the reimbursement, Aschoff does not know how many patients can actually benefit from the recent deal with Express Scripts due to the numerous payor exclusions for obesity medications.

Regarding the REMS modifications proposed by Vivus to the FDA, the analyst has yet to find a drug that had its REMS altered so soon after launch, and clearly Vivus has not sold enough drug for long enough to possibly have generated data arguing against the current REMS.

Aschoff has lowered 4Q-2012 Qsymia revenue estimate to $2 million and have cut future estimates as well. The competitive environment is only going to increase, in his view, and both Arena and Orexigen will have larger salesforces, with Orexigen having the best mix of efficacy, safety, CVOT data, and salesforce strength, and with far more minor competition from Arena, in his view.

[Related -Stocks Off Over 1 Pct After Bernanke Comments; VIVUS, Inc. (VVUS) Gains]

The brokerage, with $7 price target on the stock, widened its 2012 loss per share estimate to $1.27 from $1.23 and its 2013 loss estimate to $1.49 from $0.62.

VVUS is trading down 4.89% at $13.62 on Thursday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageMBIA Inc. (MBI) : BTI's $12 a Tough Task

MBIA Inc. (NYSE:MBI) is doing well on a day stocks are struggling The guarantee insurance company is the read on...

article imageUrban Outfitters, Inc. (URBN) Q2 Earnings Preview: A Snug Fit

Urban Outfitters, Inc. (NASDAQ:URBN) will hold a webcast to discuss its second quarter of fiscal-year 2015 read on...

article imageEstee Lauder Companies Inc. (EL) Q4 Earnings Preview: Options Player Betting On EL’s EPS Looking Pretty

Estee Lauder Companies Inc. (NYSE:EL) will release fiscal 2014 fourth quarter and full year financial read on...

article imageHerbalife Ltd. (HLF): 3 Reasons To Pay Attention to Recent Insider Buying

Well, well, well… it looks as if boardroom buyers viewed the recent selloff as an opportunity to buy. read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Top Insider Purchases: OPK, VVUS, LIOX, NTS, NSPR
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.